Brimonidine Tartrate

證據等級: L5

預測適應症: 0 個

Brimonidine Tartrate: Drug Repurposing Evaluation — Insufficient Data for Prediction

One-Sentence Summary

Brimonidine tartrate is an alpha-2 adrenergic agonist widely used for the treatment of glaucoma and ocular hypertension. The TxGNN model has not generated any predicted new indications for this drug, and key data fields (DrugBank ID, MOA, approved indication text, safety data) remain unfilled. This report serves as a data gap assessment to guide next steps for completing the evidence pack.

Quick Overview

Item	Content
Original Indication	(Data not provided in evidence pack — known clinically for glaucoma / ocular hypertension)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (No predictions, no supporting studies)
Malaysia Market Status	✓ Marketed
Number of Registrations	9
Recommended Decision	Hold

Why Was No Prediction Generated?

Brimonidine tartrate is a selective alpha-2 adrenergic receptor agonist. It reduces aqueous humour production and enhances uveoscleral outflow, thereby lowering intraocular pressure. It is also available in a topical dermal formulation for the treatment of persistent facial erythema associated with rosacea.

The TxGNN model returned an empty predicted_indications array, which typically indicates one or more of the following issues:

Missing DrugBank ID mapping — The evidence pack shows drugbank_id: null. Without a valid DrugBank identifier, the drug cannot be located in TxGNN’s knowledge graph (node.csv), and no repurposing candidates can be scored. The query log shows a DrugBank query returned 1 result, but the ID was not populated into the evidence pack.
Incomplete upstream data — The original_indications array is empty and all licence records have blank fields, suggesting the NPRA data extraction did not successfully parse structured fields for this drug.
Topical/ophthalmic route limitation — Brimonidine is predominantly used as an ophthalmic or topical agent. The TxGNN knowledge graph may have limited representation of locally-acting drugs compared to systemic therapeutics.

Until the DrugBank ID is resolved and the drug is successfully mapped into the knowledge graph, no repurposing predictions can be generated.

Clinical Trial Evidence

No predicted indication is available; therefore, no targeted clinical trial search was conducted.

Literature Evidence

No predicted indication is available; therefore, no targeted literature search was conducted.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(empty)	(empty)	(empty)	(empty)

Note: 9 registrations were identified by the NPRA query, but structured licence details (authorization number, product name, dosage form, approved indication) were not populated in the evidence pack. The raw NPRA data needs to be re-extracted and parsed.

Safety Considerations

Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, drug interactions) are currently unpopulated in the evidence pack.

Data Gap Summary

The following critical gaps must be resolved before this candidate can progress:

Gap ID	Item	Severity	Impact	Remediation
DG001	Package insert warnings & contraindications	Blocking	Cannot enter S1 safety screening	Download package insert PDF from NPRA/TFDA and parse
DG002	Mechanism of Action (MOA)	High	Affects mechanistic relevance analysis	Query DrugBank API (1 result already found)
—	DrugBank ID	Blocking	Cannot run TxGNN prediction without KG node	Map from DrugBank query result (DB00484)
—	NPRA licence details	High	Market information section is empty	Re-extract structured fields from NPRA
—	Original indication text	High	Cannot establish baseline for repurposing logic	Parse from NPRA approved indication field

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence pack is critically incomplete — no DrugBank ID mapping, no parsed licence details, no safety data, and consequently no TxGNN predictions were generated. There is insufficient information to evaluate any repurposing opportunity at this time.

To proceed, the following is needed:

Resolve DrugBank ID mapping — The query log indicates 1 DrugBank result was found; populate drugbank_id (likely DB00484 for brimonidine) and re-run TxGNN prediction
Re-extract NPRA licence data — Parse authorization numbers, product names, dosage forms, and approved indication text for all 9 registrations
Obtain package insert — Download and parse warnings, contraindications, and drug interaction information
Query DrugBank API for MOA — Retrieve mechanism of action, pharmacodynamics, and toxicity data
Re-run TxGNN pipeline — Once DrugBank ID is mapped, execute run_kg_prediction.py to generate repurposing candidates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.